

Regulation of Appetite and Satiety by Gastrointestinal Peptides**Sarah H. Mhaibes^{*1}, Najwan K. Fakree^{*} and Sonia I. Naser^{*}**^{*}Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq.**Abstract**

In recent decades, global obesity has increased significantly, causing a major health problem with associated complications and major socioeconomic issues. The central nervous system (CNS), particularly the hypothalamus, regulates food intake through sensing the metabolic signals of peripheral organs and modulating feeding behaviors. The hypothalamus interacts with other brain regions such as the brain stem to perform these vital functions. The gut plays a crucial role in controlling food consumption and energy homeostasis. The gut releases orexigenic and anorexigenic hormones that interact directly with the CNS or indirectly through vagal afferent neurons. Gastrointestinal peptides (GIP) including cholecystokinin, peptide YY, Nesfatin-1, glucagon-like peptide 1, and oxyntomodulin send satiety signals to the brain and ghrelin transmit hunger signals to the brain. The GIP is essential for the control of food consumption; thus, explain the link between the gastrointestinal tract (GIT) and the brain is important for managing obesity and its associated diseases. This review aimed to explain the role of gut peptides in satiety and hunger control.

Keywords: Obesity, Gastrointestinal peptides, Ghrelin, Oxyntomodulin.

تنظيم الشهية والشبع بواسطة الببتيدات المعدية المعوية

سارة هاشم محيبس^{*1}، نجوان قيصر فخري^{*} و سونيا عماد ناصر^{*}

^{*}فرع العلوم المختبرية السريرية، كلية الصيدلة، جامعة بغداد، بغداد، العراق .**الخلاصة**

في العقود الأخيرة، زادت السمنة العالمية بشكل كبير، مما تسبب في مشكلة صحية كبيرة مع المضاعفات المرتبطة بها والمشاكل الاجتماعية والاقتصادية الرئيسية. يلعب الجهاز العصبي المركزي، ولاسيما تحت المهاد، دوراً حاسماً في تنظيم تناول الطعام عن طريق استشعار اشارات التمثيل الغذائي للأعضاء الطرفية وتعديل سلوكيات التغذية. يتفاعل المهاد مع مناطق أخرى في الدماغ مثل جذع الدماغ لأداء هذه الوظائف الحيوية. تلعّب القناة الهضمية دوراً حاسماً في التحكم في استهلاك الغذاء وتوازن الطاقة. تطلق القناة الهضمية هرمونات التي تتفاعل مباشرة مع الجهاز العصبي المركزي أو بشكل غير مباشر من خلال الخلايا العصبية. الببتيدات المعدية المعوية بما في ذلك كوليسستوكينين، البيبتيد، الجلوكاجون و أوكسيتومودولين ترسل اشارات الشبع الى الدماغ و جريلين يرسل اشارات الجوع الى الدماغ. هرمون البيبتيد المشتق من الأمعاء ضروري للسيطرة على استهلاك الطعام. وبالتالي، فإن شرح العلاقة بين الجهاز الهضمي والدماغ مهم لإدارة السمنة والأمراض المرتبطة بها. تهدف هذه المراجعة إلى توضيح دور الببتيدات المعدية المعوية في الشبع والسيطرة على الجوع.

الكلمات المفتاحية: السمنة، الببتيدات المعدية المعوية، جريلين، أوكسيتومودولين

Introduction

The control of food intake in healthy individuals is done by gastrointestinal peptides (GIP) that stimulate hunger or satiety. Disturbance of GIP metabolism can lead to obesity⁽¹⁾. The coordination of central and peripheral signals that control energy homeostasis is vital to understand appetite control. In the body's energy balance, the central nervous system (CNS) that receives signals from the digestive tract and adipose tissue plays an indispensable role. Hunger and satiety are controlled by the brain-gut axis⁽²⁾. GIP monitor food consumption, stomach evacuation, and bowel movements, collectively control body weight over the long term⁽³⁾.

Several peptides originated from the gut inhibit food intake, specifically cholecystokinin (CCK), peptide tyrosine (PYY), glucagon-like peptide 1 (GLP-1), and nesfatin-1. In contrast, ghrelin which is centrally acting and peripherally delivered peptide stimulate food intakes⁽⁴⁾.

The worldwide spread of obesity and the major complications associated with it have induced greater necessity to understand the processes of energy balance. The present review aimed to explain the role of GIP Involved primarily in hunger and satiety regulation.

¹Corresponding author E-mail: phsarahhashim@gmail.com

Received: 14/7/2020

Accepted: 2/11/2020

Brain-Gut Food Intake Regulation

The hypothalamus is critical in the relaying of afferent signals from the gut and brainstem as well as processing efferent signals that modulate food intake and energy expenditure. The hypothalamus arcuate nucleus (ARC) is a structure located at the base of the hypothalamus, adjacent to the median eminence (ME). The latter has a more permeable blood-brain barrier (BBB), which makes the ARC neurons exposed to nutrients and gastrointestinal peptides. The ARC transmits circulatory signals to other hypothalamic zones, as well as to extrahypothalamic areas such as the mesolimbic reward system and to the hunger and satiety sites in the nucleus tractus solitarius (NTS) ⁽⁵⁾. The ARC

contains two neuronal populations in the ARC implicated in the regulation of feeding. Orexigenic neurons (i.e. stimulating appetite) express neuropeptide Y (NPY) and agouti-related protein (AgRP). Whilst anorexigenic neurons (i.e. inhibiting appetite) in the ARC express cocaine- and amphetamine-related transcript (CART) and pro-opiomelanocortin (POMC). Neuronal projections from these two populations then communicate with other hypothalamic areas involved in appetite regulation such as the Paraventricular nucleus (PVN), Dorsomedial nucleus (DMN), and Lateral hypothalamic area (LHA) ⁽⁶⁾. Table 1 explains the role of GIP in food intake control

Table1. GIP activities in food intake control ⁽⁶⁾

GIP	Receptor	Site of action	Effects on food intake
Ghrelin	ghrelin receptor	Vagal nerve Brain stem Hypothalamus	orexigenic ↑ appetite ↑ gastric motility
Nesfatin-1	Melanocortin receptor	Vagal nerve Brain stem Hypothalamus	Anorexigenic ↓ appetite
CCK	CCK1	Vagal nerve Brain stem Hypothalamus	Anorexigenic ↓ appetite ↑ gallbladder emptying ↓ gastric emptying
Peptide YY	Y2R	Vagal nerve Brain stem Hypothalamus	Anorexigenic ↓ gastric emptying ↓ intestinal motility
GLP-1	GLP-1	Vagal nerve Brain stem Hypothalamus	Anorexigenic ↑ insulin release ↓ gastric acid secretion
OXM	GLP-1 Glucagon	Hypothalamus	Anorexigenic ↑ energy expenditure ↓ gastric emptying and secretion

↑, increase; ↓, decrease; GIP "gastrointestinal peptides", GIT "gastrointestinal tract", CCK "cholecystokinin", GLP-1 "glucagon like peptide-1", PYY "Peptide YY", OXM "oxyntomodulin", Y2R "neuropeptide Y2 receptor".

Gastrointestinal Peptides Coordinating Satiety and Appetite

1- Ghrelin

Ghrelin is biosynthesized and secreted from the stomach, small intestine, pancreas and brain ⁽⁷⁾. Ghrelin is found in the bloodstream in two forms. First is deacyl-ghrelin (desacyl-ghrelin) which is more stable and higher levels than other forms. Second is the acylated form (acyl-ghrelin AG) which is the product of post-translational acylation of the hydroxyl group of the ser3 residue of the nascent ghrelin, catalyzed by ghrelin-o-acyltransferase (GOAT). This acylated form corresponds to around 20 % of the total circulating

ghrelin and is responsible for the biological activity of ghrelin. GOAT is responsible for the acylation of the proghrelin and converted to proghrelin that is proteolytically cleaved by the prohormone convertase. ⁽⁸⁾. The biological activities of acyl-ghrelin are mediated by binding to the growth hormone secretagogue receptor (GHS-R1a) ⁽⁸⁾. Acyl-ghrelin has several functions in many tissues. Acyl-ghrelin stimulates the secretion of growth hormones from the anterior pituitary gland and activates the hypothalamic orexigenic axis by inducing the secretion of neuropeptides such as

NPY, stimulating food intake and reducing energy expenditure.⁽⁹⁾ Thus, ghrelin exhibits orexigenic properties and has been targeted for the treatment of obesity. Chronic administration of ghrelin promotes weight gain and obesity⁽¹⁰⁾. The circulating concentration of orexigenic ghrelin increased in obese patients with Prader – Willi syndrome⁽¹¹⁾. In addition to its orexigenic effect mediated by neuropeptide Y, ghrelin contributes to obesity by stimulating GH secretion from the pituitary gland⁽¹²⁾.

The dimerization property of GHS-R1a with multiple G-protein coupled receptors allowing the cross-talk between many other neuropeptide systems of serotonin and dopamine. Hence, ghrelin has the potential to engage various neuropeptide systems in mood, food, and obesity^(13,14).

The ghrelinergic system mediates the non-homeostatic hedonic rewarding and motivational aspects of food intake via mesolimbic dopaminergic circuitry^(15,16).

Ghrelin receptors spread widely throughout the body, with high levels of pituitary and hypothalamic expression with lower levels of expression in peripheral tissue, especially in the pancreas, GIT, immune cells, and the heart. Further, ghrelin enhances GIT motility and diminishes insulin secretion⁽¹⁷⁾.

Patterson *et al.* reviewed many studies cored about antagonizing ghrelin action by competitive inhibition or by neutralizing ghrelin, as targets for the treatment of obesity^(18,19). Also, the antagonizing ghrelin action may be used as a treatment of nutritional disorders like cachexia and anorexia nervosa⁽³⁾.

2- Nesfatin-1

Nesfatin-1 (NF-1) was first identified in 2006 as an anorexigenic peptide. Its precursor protein, non-esterified fatty acid / nucleobinding 2 (NUCB2) is expressed in CNS and peripheral tissue.⁽²⁰⁾ NF-1 is secreted centrally from the hypothalamus and freely crosses the BBB. In addition, it is released peripherally from gastric mucosa, adipose tissue, pancreas, and testis tissue⁽²¹⁾. Many studies have shown that central or peripheral NF-1 injection significantly reduce food intake in rodents^(22,23,24). Also, NF-1 may affect absorption and digestion of food which is explained by reduced NUCB2 mRNA expression in GIT and hindered fasting gastric emptying⁽²⁵⁾. Injection of NF-1 in brain of leptin-receptor mutant rats can suppress food intake by activating the melatonin system, irrespective of the leptin pathway⁽²²⁾.

Direct inhibition of an orexigenic substance is a possible mechanism for understanding the inhibition of food intake by NF-1. In vitro study has shown that NF-1 induces hyperpolarization in ARC nuclei that are responsible for the secretion of NPY⁽²⁶⁾. Studies on various physiology parameters are ongoing to clarify differences in the NF-1 pathways. NPY and

the α -melanocyte-stimulating hormone (α -MSH) have a controversial effect on the NF-1/NUCB2 neurons of the PVN that are activated by α -MSH and inhibited by NPY; both effects are mediated by regulating cytosolic calcium ion levels⁽²⁷⁾. Finally, NF-1 has been reported to regulate gastric motility through its effect on the PVN and the LHA⁽²⁸⁾. Peripheral effects of NF-1 seem to be more concerned about decreasing gastric motility and increasing the glucose-stimulated release of insulin^(29,30).

3- Cholecystokinin

Cholecystokinin (CCK) is biosynthesized and released by endocrine I cell in the mucosal lining of the small intestine, as well as neurons of the enteric nervous system, and neurons in the brain⁽³¹⁾. Circulating CCK levels are increased at 14 minutes after food intake and persist about 3 hours; CCK is inactivated by tripeptidyl peptidase II. Fat and protein-rich foods are strong release stimuli. While, duodenal bile acids are powerful biological CCK release suppressors⁽³²⁾.

CCK actions are mediated via binding to two G protein-coupled receptors, CCKA and CCKB. CCKA exists in many tissues, including GIT, the pancreas, hepatitis, and vagal afferents, whereas CCKB is the dominant type in the CNS, especially the brain⁽³³⁾. The CCK-induced satiation by linking CCKA receptors on the vagus nerve⁽³⁴⁾. So, the CCK can, directly and indirectly, transmit satiation signals to the brain. The CCK's physiological functions are to promote enzyme release, facilitate GIT motility, and defer gastric emptying. CCK and leptin produce short-term food inhibition and promote long-term body weight loss, which can be considered as a potential target for obesity treatment⁽⁴⁾. The primary clinical area of focus for CCKA receptor agonists was obesity treatment⁽³⁵⁾. Variability in CCK-1 receptors can enhance obesity propensity. CCK seems to be more important in satiation than satiety⁽³⁶⁾.

The manipulation of CCK-satiation signals by drugs has been found to impact eating behavior by influencing meal size but not the number of meals⁽³⁷⁾. Nevertheless, the study shows that CCK has an essential role as an anti-obesity counterbalanced by reducing the food intake via raising the number of meals without altering body weight⁽³⁸⁾. Administration of CCKA receptor agonists to obese subjects has failed to reduce body weight⁽³⁹⁾. However, coadministration of CCK and leptin in rats has shown to have a synergistic effect on weight loss⁽⁴⁰⁾. It is worthy to mention that both CCKA and leptin receptors are expressed on vagal afferent neurons that may explain the synergistic effect between CCK and leptin in weight reduction⁽⁴¹⁾.

4- Peptide tyrosine-tyrosine

Peptide tyrosine-tyrosine (PYY) is anorexigenic peptide that consists of thirty-six amino acid residues. Structurally, it is characterized by the

presence of pancreatic polypeptide (PP)- fold, similar to other peptides like NPY, GIP, and PP. PYY is synthesized by the intestinal enteroendocrine L-cells of the ileum and colon along with other gut like GLP-1 and oxyntomodulin (OXM), and is secreted in response to food intake⁽⁴²⁾. PYY secretion is proportional to meals' quality, and its circulatory levels increase to up to 6 hours within 2 hours of food intake⁽⁴³⁾. There are two significant forms of PYY found in circulation, PYY1-36 and PYY3-36. PYY1-36 is cleaved into PYY3-36 by dipeptidyl peptidase 4 (DPP4). PYY3-36 may act centrally by competitive inhibition of NPY Y2 receptor (Y2R) on NPY neurons suppressing food intake. Decreased endogenous levels of PYY in obese subjects when compared to lean subjects⁽⁴⁴⁾. Obese people have lowered PYY3-36 levels while fasting PYY3-36 levels have been elevated since gastric bypass operation and other conditions associated with reduced appetite⁽⁴³⁾. It is suggested that increased fast and postprandial levels of PYY in massively obese individuals play a significant role in their dramatic weight loss after gastric sleeves⁽⁴⁵⁾.

5- Glucagon-like peptide-1

Glucagon-like peptide-1 (GLP-1) formed by differential processing of the proglucagon gene in ileum cells and colon L cells⁽⁴⁶⁾. Central and peripheral GLP-1 behaviors are essential to appetite control. In normal conditions, GLP-1 secretion triggered by intake of food rich with glucose and fatty acid, it is serving as an "incretin" and causing increased insulin secretion after food intake, thus, influencing glucose homeostasis. Other GLP-1 actions involve repression of glucagon secretion, impaired gastric emptying, and GIT motility suppression. The half-life of GLP-1 is short due to the quick degradation of an active form into inactive form, following dipeptidyl peptidase-4 (DPP-4) disconnecting 2 terminal amino acids.⁽⁴⁷⁾ GLP-1 has anorexigenic effects via the large-scale receptors in the GIT, pancreas, and brain⁽⁴⁸⁾. Also, it reduces the rate of food absorption into circulation by decrease the gastric emptying rate⁽⁴⁹⁾.

GLP-1 was the first reliable GIT hormone utilized for human medicine. Many preparations of GLP-1 receptor agonists and DPP-IV blockers for type 2 diabetes mellitus (type 2 DM) treatment are presently available⁽⁵⁰⁾. The effectiveness of GLP-1 receptor agonists in promoting weight loss at doses used to regulate diabetes has restricted effectiveness⁽⁵¹⁾.

Obesity preserves the anorectic action of GLP-1. Consequently, diminished GLP-1 secretion may lead to obesity pathogenesis. The impact of GLP-1 on appetite and food intake may help weight loss⁽⁵²⁾.

The GLP-1 normalizes glycosylated fructosamine, decrease glycated hemoglobin, and reduces body weight after 6 weeks of treatment in type 2 DM patients.⁽⁵³⁾ Therefore, GLP-1 is

considered good medicine to control appetite and treat obesity and type 2 DM⁽⁴⁵⁾.

6- Oxyntomodulin

Oxyntomodulin (OXM) is a pro-glucagon 37-amino acid peptide product, it is synthesized and secreted from the intestinal L-cells with a response to caloric consumption. OXM reduces pancreatic secretions and gastric motility and secretions and stimulates glucose metabolism⁽⁵⁴⁾. OXM joins both the glucagon and GLP-1 receptors, while its effect on appetite mediated by GLP-1 receptor since the treatment with a GLP-1 receptor blocker prevents the anorectic effects of OXM⁽⁵⁴⁾.

OXM offers an exciting possibility as an anti-obesity because of its binary actions on food intake reduction and increased energy expenditure. It acts as a glucagon receptor agonist to raise energy expenditure without effect on glucose levels. The agonist action of OXM on both GLP-1 and glucagon receptors confirmed by reduced body weight without disruption of glycemic control, and an improved lipid profile in diet-induced obese animals, which gives suggestions the future expansion of obesity therapies^(55,56).

Obesity Control with Gut Peptide Therapies

Obesity is a worldwide health problem, which is a major contributor to cardiovascular disease and cancer. The World Health Organization has forecast an overweight of about two billion adult populations and million obese by 2015⁽⁵⁷⁾. Obesity is defined as an imbalance between consumption and expenditure of energy. Food intake is regulated via orexigenic and anorexigenic peptides. A chronic imbalance between signals of hunger and satiety increases the risk of obesity⁽⁵⁸⁾.

Nearly every medicine and compartmental treatment for obesity lead to weight reduction and weight recovery. Conversely, gastric sleeve is a treatment of obesity that provides safe weight loss control for an extended period. The mechanisms following the bariatric surgery for long-term weight loss have yet to be identified; however, numerous gut hormones are involved in this; ghrelin decreases and increases in PYY and GLP-1 levels are noted after bypass surgery⁽⁵⁹⁾. Inhibiting the response of PYY and GLP-1 gave rise to appetite and increases food intake. Thus, high levels of PYY and GLP-1 play an essential role in weight loss after stomach bypass surgery⁽⁶⁰⁾. Gastric bypass surgery can not consider alone for the treatment of obesity due to its costly and major complications associated with each surgery. Pharmacotherapy is necessary, leading to substantial, treatable, continuous loss of weight, diabetes, and cardiovascular health improvement⁽⁶⁰⁾.

For the following reasons, gut hormones have developed as the main type of target management of obesity. Also, surgical treatment of obesity is known to increase the postprandial release of GIP like GLP-1, oxyntomodulins, PYY, and it is supposed to lead to many of the metabolic perks of this surgery^(60,61). The restriction of these hormones in patients with gastric bypass surgery inverts some advantages of surgery such as decreased appetite⁽⁶²⁾. The PYY and OXM combination causes a preferable decrease of appetite relative to the hormone alone⁽⁶³⁾. Also, when giving oral PYY3-36 together with GLP-17-36 amide in conjunction with sodium N-caprylate to 12 healthy human-caused a significant reduction of energy consumption in the dinner served 15 minutes later⁽⁶⁴⁾. Oxyntomodulin and PYY hormones can also reproduce the levels of post-prandial intestinal hormones shown after gastric bypass when given to 10 obese healthy individuals as a subcutaneous infusion for 10 hours⁽⁶⁵⁾. Dual and even three-fold agonists of the intestinal hormones can serve as the basis for optimal body weight loss and a new obesity treatment strategy.

However, many remedies do not produce a dramatic weight loss of over 5 percent and cause serious side effect like fatigue, heart disease, and neurological effects^(66,67). Thus, hormones must control food consumption, digestion, and, therefore, bodyweight without systemic administration's dangerous effects. Due to the administration of nutrients or medication compounds, the enter endocrine network could raise weight reduction efficiency and mimic physiological sensors of feeling full and appetite control⁽⁶⁸⁾. To induce endogenous gut hormone discharge, nutritional stimulation of the enter endocrine L cell taste receptors into the distal small intestine and colon must be regarded. In reality, sweet taste receptor in vitro stimulation in immortalized and primary L cell crops induces hormone release, including OXM, GLP-1, and PYY⁽⁶⁹⁾. Thus, it is promising to specifically target nutrient receptors via oral or rectal administration with further study is required. Endogenous secretion of GIP may have an appropriate therapeutic choice for diabetes type 2 and obesity⁽⁷⁰⁾.

Conclusion

The hypothalamus combines GIT signals with signals of other peripheral tissues or external environments. The processing of all input signals in CNS produces different compensatory responses to maintain energy homeostasis. The role of peptide hormones derived from the GIT is controlling body weight and energy homeostasis. Decrease appetite increases satiety with enhancing energy expenditure are criteria required to control the body weight. The characteristic of GIP fulfills these criteria make them more effective therapeutic approaches against obesity and obesity-related diseases. Further research needed to explain the effectiveness of gut peptide as an effective therapeutic strategy for

weight gain to reduce morbidity and mortality related to obesity.

Acknowledgments

The authors are very thankful for the support from University of Baghdad, College of Pharmacy, Baghdad- Iraq.

References

1. Mithieux G. Nutrient control of hunger by extrinsic gastrointestinal neurons. *Trends Endocrinol Metab.* 2013; 24:378-384.
2. Suzuki K, Simpson KA, Minnion JS, et al. The role of gut hormones and the hypothalamus in appetite regulation. *Endocr J.* 2010; 57: 359-72.
3. Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. *Ther Adv Chronic Dis.* 2014; 5:4-14.
4. Suzuki K, Jayasena CN, Bloom SR. Obesity and appetite control. *Experimental diabetes research.* 2012 Oct;2012.
5. Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. *Disease models & mechanisms.* 2017;10(6):679-89.
6. Miller GD. Appetite regulation: hormones, peptides, and neurotransmitters and their role in obesity. *American journal of lifestyle medicine.* 2019 Nov;13(6):586-601.
7. Sato T, Nakamura Y, Shiimura Y, Ohgusu H, Kangawa K, Kojima M. Structure, regulation and function of ghrelin. *The Journal of Biochemistry.* 2012;151(2):119-28.
8. Pereira JA, Silva FC, de Moraes-Vieira PM. The impact of ghrelin in metabolic diseases: an immune perspective. *Journal of diabetes research.* 2017 Sep 7;2017.
9. Sato T, Nakamura Y, Shiimura Y, Ohgusu H, Kangawa K, Kojima M. Structure, regulation and function of ghrelin. *The Journal of Biochemistry.* 2012 Feb 1;151(2):119-28.
10. Lean ME, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? *International journal of obesity.* 2016 Apr;40(4):622-32.
11. Allas S, Caixàs A, Poitou C, Coupaye M, Thuilleaux D, Lorenzini F, Diene G, Crinò A, Illouz F, Grugni G, Potvin D. AZP-531, An unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. *PloS one.* 2018;13(1): e0190849.
12. Howick K, Griffin BT, Cryan JF, Schellekens H. From Belly to Brain: Targeting the ghrelin receptor in appetite and food intake regulation. *Int J Mol Sci.* 2017;18(2):273.
13. Schellekens H, Dinan TG, Cryan JF. Ghrelin at the interface of obesity and reward. In *Vitamins & Hormones.* 2013; 91: 285-323.

14. Schellekens H, Dinan TG, Cryan JF. Taking two to tango: a role for ghrelin receptor heterodimerization in stress and reward. *Frontiers in Neuroscience*. 2013 ;30;7:148.
15. Perelló M, Zigman JM. The role of ghrelin in reward-based eating. *Biological Psychiatry*. 2012;72(5):347-53.
16. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. *Molecular and Cellular Endocrinology*. 2011;340(1):80-7.
17. Schloegl H, Percik R, Horstmann A, Villringer A, Stumvoll M. Peptide hormones regulating appetite-focus on neuroimaging studies in humans. *Diabetes Metab Res Rev*. 2011; 27: 104.
18. Patterson M., Bloom S.R., Gardiner J.V. Ghrelin and appetite control in humans—potential application in the treatment of obesity. *Peptides* .2011;32: 2290–2294.
19. Vodnik M., Strukelj B., Lunder M. Ghrelin receptor ligands reaching clinical trials: from peptides to peptidomimetics; from agonists to antagonists. *Horm. Metab. Res*.2016;48: 1–15
20. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. *Nature* 2006; 443:709-712.
21. Stengel A, Tach Y. Nesfatin-1 role as possible new potent regulator of food intake. *Regul Pept*. 2010;163:18–23
22. Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. *Hippokratia* 2015;19(1):4
23. GonzalezR, MohanH,UnniappanS. Nucleobindins: bioactive precursor proteins encoding putative endocrine factors? *Gen Comp Endocrinol*. 2012;176 (3):341–6
24. Goebel-Stengel M, Wang L. Central and peripheral expression and distribution of NUCB2/nesfatin-1. *Current Pharmaceutical Design*. 2013 Dec 1;19(39):6935-40.
25. Shimizu H, Tanaka M, Osaki A. Transgenic mice overexpressing nesfatin/nucleobindin-2 are susceptible to high-fat diet-induced obesity. *Nutr Diabetes*.2016;6: e201
26. Stengel A, Taché Y. Role of brain NUCB2/nesfatin-1 in the regulation of food intake. *Curr Pharm Des*. 2013; 19: 6955-6959.
27. Sedbazar U, Ayush EA, Maejima Y, Yada T. Neuropeptide Y and α -melanocyte-stimulating hormone reciprocally regulate nesfatin-1 neurons in the paraventricular nucleus of the hypothalamus. *Neuroreport*. 2014; 25: 1453-1458.
28. Guo FF, Xu L, Gao SL, Sun XR, Li ZL, Gong YL. The effects of nesfatin-1 in the paraventricular nucleus on gastric motility and its potential regulation by the lateral hypothalamic area in rats. *J Neurochem*. 2015; 132: 266-275
29. Gonzalez R, Perry RL, Gao X, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. *Endocrinology* 2011; 152:3628-3637.
30. Riva M, Nitert MD, Voss U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. *Cell Tissue Res*. 2011; 346:393-405.
31. Rehfeld JF. Cholecystokinin—from local gut hormone to ubiquitous messenger. *Frontiers in Endocrinology*. 2017 Apr 13;8:47.
32. Delzenne N, Blundell J, Brouns F, Cunningham K, De Graaf K, Erkner A, Lluh A, Mars M, Peters HP, Westerterp-Plantenga M. Gastrointestinal targets of appetite regulation in humans. *Obesity reviews*. 2010 Mar;11(3):234-50.
33. Airaodion AI, Ogbuagu U, Oloruntoba AP, Agunbiade AP, Airaodion EO, Mokelu IP, Ekeh SC. Biochemical mechanisms involved in the regulation of appetite and weight-review. *International Journal of Research*. 2019 Feb;6(2):397-409.
34. de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. *The Journal of Physiology*. 2016 Oct 15;594(20):5791-815.
35. Miller LJ, Desai AJ. Metabolic actions of the type 1 cholecystokinin receptor: its potential as a therapeutic target. *Trends in Endocrinology & Metabolism*. 2016 Sep 1;27(9):609-19.
36. Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. *Physiological reviews*. 2017 Jan;97(1):411-63.
37. Pathak V, Flatt PR, Irwin N. Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. *Peptides*. 2018 Feb 1;100:229-35.
38. Udenigwe CC, Di Stefano E, Tsige FF, Gunenc A. Pancreas-Stimulating Foods: Cholecystokinin Enhancers. *Encyclopedia of food chemistry*.2019:487-496.
39. Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development *Endocrinology*. 2009; 150:2526-30.
40. Owyang C, Heldsinger A. Vagal control of satiety and hormonal regulation of appetite. *Journal of Neurogastroenterology and Motility*. 2011 Oct;17(4):338.
41. Ueno H, Nakazato M. Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in

- appetite regulation. *Journal of diabetes investigation*. 2016 Nov;7(6):812-8.
42. Stadlbauer U, Woods SC, Langhans W, Meyer U. PYY3–36: beyond food intake. *Frontiers in Neuroendocrinology*. 2015 Jul 1;38:1-1.
 43. Price SL, Bloom SR. Protein PYY and its role in metabolism. *Front Horm Res*. 2014; 42:147-54.
 44. Batterham, R. L., Le Roux, C. W., Cohen, M. A., Park, A. J., Ellis, S. M., Patterson, M., et al. Pancreatic polypeptide reduces appetite and food intake in humans. *J Clin Endocrinol Metab*. 2003; 88(8): 3989–3992.
 45. le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. *Ann Surg*. 2007; 246(5): 780–785.
 46. Fujita Y, Yanagimachi T, Takeda Y, Honjo J, Takiyama Y, Abiko A, Makino Y, Haneda M. Alternative form of glucose-dependent insulinotropic polypeptide and its physiology. *Journal of Diabetes Investigation*. 2016 Apr;7:33-7.
 47. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. *Trends Endocrinol Metab*. 2013; 24:85-91
 48. Meier JJ, Ritter PR, Jacob A, Menge BA, Deacon CF, Schmidt WE, Nauck MA, Holst JJ. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans. *The Journal of Clinical Endocrinology & Metabolism*. 2010 Aug 1;95(8):4061-5.
 49. Kanoski SE, Fortin SM, Arnold M, et al. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. *Endocrinology*. 2011; 152: 3103-12.
 50. Umpierrez GE, Meneghini L. Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. *Endocr Pract*. 2013; 19:718-28.
 51. Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? *Trends Endocrinol Metab*. 2013; 24:145-52.
 52. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. *Diabetologia*. 2017 Oct 1;60(10):1851-61.
 53. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6- week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet*. 2002; 359:824---30.
 54. Price SL, Minnion JS, Bloom SR. Increased food intake with oxyntomodulin analogues. *Peptides*. 2015 Nov 1;73:95-100.
 55. Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, Chicchi G, Erion MD, Gidda J, Thornberry NA, Tschöp MH, Marsh DJ. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. *Peptide Science*. 2012;98(5):443-50.
 56. Pocius, A., Carrington, P., Adams, J., Wright, M., Eiermann, G., Zhu, L. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. *Diabetes*. 2009; 58: 2258–2266.
 57. World Health Organization (WHO). *Obesity*. Geneva: WHO; 2008.
 58. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. *Diabetes & Metabolism journal*. 2012;36(6):391-8.
 59. Suzuki K, Jayasena CN, Bloom SR. The gut hormones in appetite regulation. *Journal of Obesity*. 2011 Jan 1;2011.
 60. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. *Ann Surg*, 2007;246:780-785.
 61. Tan T, Behary P, Tharakan G, et al. The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. *J Clin Endocrinol Metab*. 2017; 102:2364–2372.
 62. Svane MS, Jørgensen NB, Bojsen-Møller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. *Int J Obes*. 2016; 40 (11):1699–1706.
 63. Field, B., Wren, A., Peters, V., Baynes, K., Martin, N., Patterson, M. et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. *Diabetes*. 2010; 59: 1635–1639.
 64. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. *Am J Clin Nutr*. 2010; 92:810- 817.
 65. Tan T, Behary P, Tharakan G, et al. The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. *J Clin Endocrinol Metab*. 2017;102(7):2364-2372.
 66. McGavigan AK, Murphy KG: Gut hormones: the future of obesity treatment? *Br J Clin Pharmacol*. 2012; 74:911-919.

67. Cheung BM, Cheung TT, Samaranyake NR: Safety of antiobesity drugs. *Ther Adv Drug Saf* .2013; 4: 171–181.
68. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM: Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. *Proc Natl Acad Sci USA* .2007; 104: 15069–15074.
69. Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J, Beglinger C: The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). *Clin Nutr*. 2011; 30: 524–532.
70. Posovszky C, Wabitsch M. Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 2: therapeutic potential of enteroendocrine cells in the treatment of obesity. *Hormone Research in Paediatrics*. 2015;83(1):11-8.

